Project Details
| Acronym | CS3002-101 |
|---|---|
| Status | Active |
| Effective start/end date | 30/10/20 → 24/09/25 |
A phase 1, open-label, multi-dose, dose escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and anti-tumor activities of CS3002, a CDK4/6 inhibitor, in subjects with advance solid tumors
- Park, John (Primary Chief Investigator)
- Sabanathan, Dhanusha (Associate Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research